"The problem I have with CORR is my being unable to see why reducing the death rate or heart attack rate from 15.7 per thousand down to 14.2 is dramatic."
If you were part of that 1.5% you'd be singing a different tune. Remember, too, that Integrilin is superior to its competitors for other reasons too. BTW, pulled this off Dow Jones:
"Small Biotech Cos To Gain Mkt Share With New Therapies
"Dow Jones Newswires
"NEW YORK -- While larger biotechnology companies have been the primary force behind the sector's recent lift, their smaller counterparts are gaining strength, said Jim McCamant, Editor of the Medical Technology Stock Letter.
"We have had some big moves" in Amgen Inc. (AMGN) and Biogen Inc. (BGEN), McCamant told CNBC Friday, "and that is starting to spread out."
"Progress in biotechnology has been steady, but stock prices have not reflected the leaps in new therapies and product introductions.
"But finally the progress has been so obvious that people are going to have to take notice," McCamant said. "We have been talking about the Internet, but biotech is the other area where there are really no limits."
"He recommends buying a basket of diversified biotechnology stocks.
"I think you really want to look at individual companies," he said, "and the smaller the company, the more diversification you need."
"McCamant likes Isis Pharmaceuticals Inc. (ISIP), COR Therapeutics Inc. (CORR), ImClone Systems Inc. (IMCL), ImmunoGen Inc. (IMGN) and Shaman Pharmaceuticals Inc. (SHMN).
"He also suggests investors look to the large biotech firm company Chiron Corp. (CHIR)."
- Amy Hughes; 201-938-5171
###### ######
Bob |
